Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins

Chuanhao Tang; Zaizai Dong; Shi Yan; Bing Liu; Zhiying Wang; Long Cheng; Feng Liu; Hong Sun; Yimeng Du; Lu Pan; Yuhao Zhou; Zhiyuan Jin; Libo Zhao; Nan Wu; Lingqian Chang; Xiaojie Xu

doi:10.1016/j.bios.2024.116748

Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins

Chuanhao Tang
, Zaizai Dong^*
, Shi Yan
, Bing Liu
, Zhiying Wang
, Long Cheng
, Feng Liu
, Hong Sun
, Yimeng Du
, Lu Pan
, Yuhao Zhou
, Zhiyuan Jin
, Libo Zhao
, Nan Wu^*
, Lingqian Chang^*
, Xiaojie Xu^*

^*Corresponding author for this work

School of Engineering Medicine

Beijing Institute of Biotechnology
Peking University
Beihang University
Anhui Medical University
Capital Medical University
Ltd.

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Extracellular vesicles (EVs) are considered as promising candidates for predicting patients who respond to immunotherapy. Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges. In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level). Ten biomarkers (including 5 RNAs and 5 proteins) from patients’ EVs are successfully detected on one chip, and the comprehensive markers show increased accuracy (AUC 0.911) than the individual marker for the efficacy prediction of immunotherapy. This platform provides a high-throughput yet sensitive strategy for screening immunotherapy markers in clinical.

Original language	English
Article number	116748
Journal	Biosensors and Bioelectronics
Volume	267
DOIs	https://doi.org/10.1016/j.bios.2024.116748
State	Published - 1 Jan 2025

Keywords

Aptamer
CRISPR/Cas
Extracellular vesicle
Immunotherapy
Microfluidic chip

Access to Document

10.1016/j.bios.2024.116748

Cite this

Tang, C., Dong, Z., Yan, S., Liu, B., Wang, Z., Cheng, L., Liu, F., Sun, H., Du, Y., Pan, L., Zhou, Y., Jin, Z., Zhao, L., Wu, N., Chang, L., & Xu, X. (2025). Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins. Biosensors and Bioelectronics, 267, Article 116748. https://doi.org/10.1016/j.bios.2024.116748

@article{a636d6742c3646269fd1b833d0d9f2aa,

title = "Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins",

abstract = "Extracellular vesicles (EVs) are considered as promising candidates for predicting patients who respond to immunotherapy. Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges. In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level). Ten biomarkers (including 5 RNAs and 5 proteins) from patients{\textquoteright} EVs are successfully detected on one chip, and the comprehensive markers show increased accuracy (AUC 0.911) than the individual marker for the efficacy prediction of immunotherapy. This platform provides a high-throughput yet sensitive strategy for screening immunotherapy markers in clinical.",

keywords = "Aptamer, CRISPR/Cas, Extracellular vesicle, Immunotherapy, Microfluidic chip",

author = "Chuanhao Tang and Zaizai Dong and Shi Yan and Bing Liu and Zhiying Wang and Long Cheng and Feng Liu and Hong Sun and Yimeng Du and Lu Pan and Yuhao Zhou and Zhiyuan Jin and Libo Zhao and Nan Wu and Lingqian Chang and Xiaojie Xu",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",

year = "2025",

month = jan,

day = "1",

doi = "10.1016/j.bios.2024.116748",

language = "英语",

volume = "267",

journal = "Biosensors and Bioelectronics",

issn = "0956-5663",

publisher = "Elsevier Ltd",

}

Tang, C, Dong, Z, Yan, S, Liu, B, Wang, Z, Cheng, L, Liu, F, Sun, H, Du, Y, Pan, L, Zhou, Y, Jin, Z, Zhao, L, Wu, N, Chang, L & Xu, X 2025, 'Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins', Biosensors and Bioelectronics, vol. 267, 116748. https://doi.org/10.1016/j.bios.2024.116748

TY - JOUR

T1 - Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins

AU - Tang, Chuanhao

AU - Dong, Zaizai

AU - Yan, Shi

AU - Liu, Bing

AU - Wang, Zhiying

AU - Cheng, Long

AU - Liu, Feng

AU - Sun, Hong

AU - Du, Yimeng

AU - Pan, Lu

AU - Zhou, Yuhao

AU - Jin, Zhiyuan

AU - Zhao, Libo

AU - Wu, Nan

AU - Chang, Lingqian

AU - Xu, Xiaojie

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Extracellular vesicles (EVs) are considered as promising candidates for predicting patients who respond to immunotherapy. Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges. In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level). Ten biomarkers (including 5 RNAs and 5 proteins) from patients’ EVs are successfully detected on one chip, and the comprehensive markers show increased accuracy (AUC 0.911) than the individual marker for the efficacy prediction of immunotherapy. This platform provides a high-throughput yet sensitive strategy for screening immunotherapy markers in clinical.

AB - Extracellular vesicles (EVs) are considered as promising candidates for predicting patients who respond to immunotherapy. Nevertheless, simultaneous detection of multiple EVs markers still presents significant technical challenges. In this work, we developed a high-throughput microdroplet-enhanced chip (MEC) platform, which utilizes thousands of individual microchambers (∼pL) as reactors, accelerating the detection efficiency of the CRISPR/Cas systems and increasing the sensitivity by up to 100-fold (aM level). Ten biomarkers (including 5 RNAs and 5 proteins) from patients’ EVs are successfully detected on one chip, and the comprehensive markers show increased accuracy (AUC 0.911) than the individual marker for the efficacy prediction of immunotherapy. This platform provides a high-throughput yet sensitive strategy for screening immunotherapy markers in clinical.

KW - Aptamer

KW - CRISPR/Cas

KW - Extracellular vesicle

KW - Immunotherapy

KW - Microfluidic chip

UR - https://www.scopus.com/pages/publications/85203619245

U2 - 10.1016/j.bios.2024.116748

DO - 10.1016/j.bios.2024.116748

M3 - 文章

C2 - 39276441

AN - SCOPUS:85203619245

SN - 0956-5663

VL - 267

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

M1 - 116748

ER -

Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this